Park Yo Seph, Lee Yukyeong, Choi Na Young, Hwang Han Sung, Rose-John Stefan, Zenke Martin, Ko Kinarm
Department of Stem Cell Biology, Konkuk University School of Medicine, Seoul, 05029, South Korea.
Department of Stem Cell Research, TJC Life Research and Development Center, TJC Life, Seoul, 06698, South Korea.
Biochem Biophys Rep. 2022 Jan 27;29:101214. doi: 10.1016/j.bbrep.2022.101214. eCollection 2022 Mar.
Umbilical cord blood (UCB) is an alternative source of allogeneic hematopoietic stem cells (HSCs) for transplantation to treat various hematological disorders. The major limitation to the use of UCB-derived HSCs (UCB-HSCs) in transplantation, however, is the low numbers of HSCs in a unit of cord blood. To overcome this limitation, various cytokines or small molecules have been used to expand UCB-HSCs ex vivo. In this study, we investigated a synergistic effect of the combination of HIL-6, SR1, and UM171 on UCB-HSC culture and found that this combination resulted in the highest number of CD34 cells. These results suggest that the combination of SR1, UM171 and HIL-6 exerts a synergistic effect in the proliferation of HSCs from UCB and thus, SR1, UM171 and HIL-6 is the most suitable combination for obtaining HSCs from UCB for clinical transplantation.
脐带血(UCB)是用于移植以治疗各种血液系统疾病的异基因造血干细胞(HSC)的替代来源。然而,在移植中使用脐带血来源的造血干细胞(UCB-HSC)的主要限制是一单位脐带血中造血干细胞数量较少。为克服这一限制,已使用各种细胞因子或小分子在体外扩增UCB-HSC。在本研究中,我们研究了HIL-6、SR1和UM171组合对UCB-HSC培养的协同作用,发现该组合产生的CD34细胞数量最多。这些结果表明,SR1、UM171和HIL-6的组合在脐带血造血干细胞增殖中发挥协同作用,因此,SR1、UM171和HIL-6是从脐带血中获取造血干细胞用于临床移植的最合适组合。